Scientific References

  1. CDC Report on Diabetes and Prediabetes https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html [Last Accesssed 20/10/2017]
  2. Chen, L., Magliano, D. J., & Zimmet, P. Z. (2012). The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nature Reviews Endocrinology, 8(4), 228-236.
  3. American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes care. 2013 Apr 1;36(4):1033-46.
  4. Zhuo X, Zhang P, Barker L, Albright A, Thompson TJ, Gregg E. The lifetime cost of diabetes and its implications for diabetes prevention. Diabetes care. 2014 Sep 1;37(9):2557-64.
  5. https://commons.wikimedia.org/wiki/File:Watermelon_seedless.jpg
  6. Melons and Morning Glories, 1813, by Raphaelle Peale
  7. The 5,000-Year Secret History of the Watermelon, By Mark Strauss, National Geographic, PUBLISHED AUGUST 21, 2015
  8. Prof. Dr. Otto Wilhelm Thomé Flora von Deutschland, Österreich und der Schweiz 1885, Gera, Germany
  9. http://www.nytimes.com/2013/05/26/opinion/sunday/breeding-the-nutrition-out-of-our-food.html?pagewanted=all&_r=0
  10. http://www.newenglandhistoricalsociety.com/legend-baldwin-apple/
  11. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes research and clinical practice. 2014 Feb 1;103(2):137-49.
  12. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. The Lancet. 2005 Apr 15;365(9467):1333-46.
  13. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. BioMed Research International. 2010 Apr 26;2010.
  14. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006 Dec 14;444(7121):840.Daneman D. Type 1 diabetes. The Lancet. 2006 Mar 17;367(9513):847-58.
  15. Daneman D. Type 1 diabetes. The Lancet. 2006 Mar 17;367(9513):847-58.
  16. Popkin BM. Urbanization, lifestyle changes and the nutrition transition. World development. 1999 Nov 30;27(11):1905-16.
  17. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D. Prevalence of diabetes among men and women in China. New England Journal of Medicine. 2010 Mar 25;362(12):1090-101.
  18. Schulz LO, Bennett PH, Ravussin E, Kidd JR, Kidd KK, Esparza J, Valencia ME. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the US. Diabetes Care. 2006 Aug 1;29(8):1866-71.
  19. Smith U. Abdominal obesity: a marker of ectopic fat accumulation. The Journal of clinical investigation. 2015 May 1;125(5):1790.
  20. Rasouli N, Molavi B, Elbein SC, Kern PA. Ectopic fat accumulation and metabolic syndrome. Diabetes, Obesity and Metabolism. 2007 Jan 1;9(1):1-0.
  21. Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. Jama. 2012 Sep 19;308(11):1150-9.
  22. Clark ML, Utz SW. Social determinants of type 2 diabetes and health in the United States. World journal of diabetes. 2014 Jun 15;5(3):296.
  23. Gordon C, Purciel-Hill M, Ghai NR, Kaufman L, Graham R, Van Wye G. Measuring food deserts in New York City’s low-income neighborhoods. Health & place. 2011 Mar 1;17(2):696-700.
  24. Lee TC, Glynn RJ, Peña JM, Paynter NP, Conen D, Ridker PM, Pradhan AD, Buring JE, Albert MA. Socioeconomic status and incident type 2 diabetes mellitus: data from the Women’s Health Study. PloS one. 2011 Dec 14;6(12):e27670.
  25. Babey SH, Diamant AL, Hastert TA, Harvey S. Designed for disease: the link between local food environments and obesity and diabetes. UCLA Center for Health Policy Research. 2008 Apr 1.
  26. Prasad RB, Groop L. Genetics of type 2 diabetes—pitfalls and possibilities. Genes. 2015 Mar 12;6(1):87-123.
  27. Lyssenko V, Groop L, Prasad RB. Genetics of type 2 diabetes: it matters from which parent we inherit the risk. The review of diabetic studies: RDS. 2015;12(3-4):233.
  28. Keaton JM, Hellwege JN, Ng MC, Palmer ND, Pankow JS, Fornage M, Wilson JG, Correa A, Rasmussen-Torvik LJ, Rotter JI, Chen YD. Genome-wide interaction with insulin secretion loci reveals novel loci for type 2 diabetes in African Americans. PloS one. 2016 Jul 22;11(7):e0159977.
  29. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care. 2014 Jan 1;37(Supplement 1):S81-90.
  30. http://www.diabetes.co.uk/body/insulin.html
  31. http://www.medscape.org/viewarticle/483307_6
  32. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. The Lancet. 2014 Jan 10;383(9911):69-82.
  33. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. Bmj. 2004 Mar 25;328(7442):750-4.
  34. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinology and metabolism clinics of North America. 2010 Sep 30;39(3):481-97.
  35. Ozougwu JC, Obimba KC, Belonwu CD, Unakalamba CB. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. Journal of Physiology and Pathophysiology. 2013 Sep;4(4):46-57.
  36. http://www.webmd.com/diabetes/diabetes-blurred-vision
  37. http://www.diabetes.co.uk/symptoms/unexplained-weight-loss.html
  38. Daneman D. Type 1 diabetes. The Lancet. 2006 Mar 17;367(9513):847-58.
  39. http://www.diabetes.co.uk/diabetes-complications/short-term-complications.html
  40. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. BioMed Research International. 2010 Apr 26;2010.
  41. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006 Dec 14;444(7121):840.
  42. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. The Lancet. 2005 Apr 15;365(9467):1333-46.
  43. Chen, L., Magliano, D. J., & Zimmet, P. Z. (2012). The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nature Reviews Endocrinology, 8(4), 228-236.
  44. Popkin BM. Urbanization, lifestyle changes and the nutrition transition. World development. 1999 Nov 30;27(11):1905-16.
  45. Schulz LO, Bennett PH, Ravussin E, Kidd JR, Kidd KK, Esparza J, Valencia ME. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the US. Diabetes Care. 2006 Aug 1;29(8):1866-71.
  46. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. Jama. 2015 Sep 8;314(10):1021-9.
  47. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Population health metrics. 2010 Oct 22;8(1):29.
  48. Nadeau KJ, Anderson BJ, Berg EG, Chiang JL, Chou H, Copeland KC, Hannon TS, Huang TT, Lynch JL, Powell J, Sellers E. Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities. Diabetes Care. 2016 Sep 1;39(9):1635-42.
  49. Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ open. 2016 Jan 1;6(1):e010210.
  50. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/nerve-damage-diabetic-neuropathies.
  51. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical diabetes. 2008 Apr 1;26(2):77-82.
  52. Pitocco D, Tesauro M, Alessandro R, Ghirlanda G, Cardillo C. Oxidative stress in diabetes: implications for vascular and other complications. International journal of molecular sciences. 2013 Oct 30;14(11):21525-50.
  53. Reusch JE. Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?. Journal of Clinical Investigation. 2003 Oct 1;112(7):986.
  54. Cardoso CR, Leite NC, Dib E, Salles GF. Predictors of Development and Progression of Retinopathy in Patients with Type 2 Diabetes: Importance of Blood Pressure Parameters. Scientific Reports. 2017;7.
  55. https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/basics/causes/con-20023311
  56. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiological reviews. 2013 Jan 1;93(1):137-88.
  57. https://www.mayoclinic.org/diseases-conditions/diabetic-nephropathy/symptoms-causes/syc-20354556
  58. Pálsson R, Patel UD. Cardiovascular complications of diabetic kidney disease. Advances in chronic kidney disease. 2014 May 31;21(3):273-80.
  59. https://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/causes/con-20033336
  60. Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes care. 1983 Jan 1;6(1):87-91.
  61. MEMBERS WG, Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. circulation. 2014 Jan 21;129(3):e28.
  62. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength?. World journal of diabetes. 2014 Aug 15;5(4):444.
  63. Ledru F, Ducimetière P, Battaglia S, Courbon D, Beverelli F, Guize L, Guermonprez JL, Diébold B. New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. Journal of the American College of Cardiology. 2001 May 31;37(6):1543-50.
  64. Burchfiel CM, Reed DM, Marcus EB, Strong JP, Hayashi T. Association of diabetes mellitus with coronary atherosclerosis and myocardial lesions: an autopsy study from the Honolulu Heart Program. American journal of epidemiology. 1993 Jun 15;137(12):1328-40.
  65. Kayama Y, Raaz U, Jagger A, Adam M, Schellinger IN, Sakamoto M, Suzuki H, Toyama K, Spin JM, Tsao PS. Diabetic cardiovascular disease induced by oxidative stress. International journal of molecular sciences. 2015 Oct 23;16(10):25234-63.
  66. Lee M, Saver JL, Hong KS, Song S, Chang KH, Ovbiagele B. Effect of pre-diabetes on future risk of stroke: meta-analysis. BMJ. 2012 Jun 7;344:e3564.
  67. Khoury, Jane C. et al. “Diabetes: A Risk Factor for Ischemic Stroke in a Large Bi-Racial Population.” Stroke; a journal of cerebral circulation 44.6 (2013): 1500–1504. PMC. Web. 24 Oct. 2017.
  68. Banerjee C, Moon YP, Paik MC, Rundek T, Mora-McLaughlin C, Vieira JR, Sacco RL, Elkind MS. Duration of diabetes and risk of ischemic stroke. Stroke. 2012 May 1;43(5):1212-7.
  69. Weinberg AE, Eisenberg M, Patel CJ, Chertow GM, Leppert JT. Diabetes severity, metabolic syndrome, and the risk of erectile dysfunction. The journal of sexual medicine. 2013 Dec 1;10(12):3102-9.
  70. Binmoammar TA, Hassounah S, Alsaad S, Rawaf S, Majeed A. The impact of poor glycaemic control on the prevalence of erectile dysfunction in men with type 2 diabetes mellitus: a systematic review. JRSM open. 2016 Feb 12;7(3):2054270415622602.
  71. Traish AM, Feeley RJ, Guay A. Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. The FEBS journal. 2009 Oct 1;276(20):5755-67.
  72. Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, Pouwer F, European Depression in Diabetes (EDID) Research Consortium. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis.
  73. van Dooren FE, Nefs G, Schram MT, Verhey FR, Denollet J, Pouwer F. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PloS one. 2013 Mar 5;8(3):e57058.
  74. Holt RIG, de Groot M, Golden SH. Diabetes and Depression. Current diabetes reports. 2014;14(6):491. doi:10.1007/s11892-014-0491-3.
  75. Penckofer S, Doyle T, Byrn M, Lustman PJ. State of the science: depression and type 2 diabetes. Western journal of nursing research. 2014 Oct;36(9):1158-82.
  76. Taylor KS, Heneghan CJ, Farmer AJ, Fuller AM, Adler AI, Aronson JK, Stevens RJ. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large UK primary care database. Diabetes Care. 2013 Aug 1;36(8):2366-71.
  77. Buchanan TA, Xiang AH. Gestational diabetes mellitus. Journal of Clinical Investigation. 2005 Mar 1;115(3):485.
  78. Tieu J, Crowther CA, Middleton P. Dietary advice in pregnancy for preventing gestational diabetes mellitus. Cochrane Database of Systematic Reviews. 2007(2).
  79. http://www.medscape.org/viewarticle/570553_1
  80. https://beyondtype1.org/what-is-monogenic-diabetes/
  81. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. Jama. 2016 Jun 7;315(21):2284-91.
  82. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006 Dec 14;444(7121):840.
  83. Smith U. Abdominal obesity: a marker of ectopic fat accumulation. The Journal of clinical investigation. 2015 May 1;125(5):1790.
  84. Rasouli N, Molavi B, Elbein SC, Kern PA. Ectopic fat accumulation and metabolic syndrome. Diabetes, Obesity and Metabolism. 2007 Jan 1;9(1):1-0.
  85. Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. Jama. 2012 Sep 19;308(11):1150-9.
  86. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian journal of medical research. 2007 Mar 1;125(3):217.
  87. Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. The Journal of Clinical Endocrinology & Metabolism. 2001 Nov 1;86(11):5366-71.
  88. Boden G. Obesity and free fatty acids. Endocrinology and metabolism clinics of North America. 2008 Sep 30;37(3):635-46.
  89. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI. Mechanism of free fatty acid-induced insulin resistance in humans. Journal of Clinical Investigation. 1996 Jun 15;97(12):2859.
  90. Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. American Journal of Physiology-Endocrinology and Metabolism. 2007 Jun 1;292(6):E1775-81.
  91. Aganović I, Dušek T. Pathophysiology of metabolic syndrome. Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia. 2014.
  92. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. Journal of Clinical Investigation. 2006 Jul 3;116(7):1793.
  93. Ye J. Mechanisms of insulin resistance in obesity. Frontiers of medicine. 2013 Mar 1;7(1):14-24.
  94. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care. 2014 Jan 1;37(Supplement 1):S81-90.Tabá G, Herder C, Rathmann W, Brunner E, Kivimäk M. Prediabetes: a high-risk state for developing diabetes. Lancet. 2012 Jun 16;379(9833):2279-90.
  95. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. Journal of the American College of Cardiology. 2012 Feb 14;59(7):635-43.
  96. Tabá G, Herder C, Rathmann W, Brunner E, Kivimäk M. Prediabetes: a high-risk state for developing diabetes. Lancet. 2012 Jun 16;379(9833):2279-90.
  97. Meyer C, Pimenta W, Woerle HJ, Van Haeften T, Szoke E, Mitrakou A, Gerich J. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes care. 2006 Aug 1;29(8):1909-14.
  98. Sprague RS, Ellsworth ML. Vascular disease in pre-diabetes: new insights derived from systems biology. Missouri medicine. 2010 Jul;107(4):265.
  99. Kodali VR, Ali I. Prediabetes: the cat is out!. International Journal of Diabetes in Developing Countries. 2016 Jun 1;36(2):143-5.
  100. Eriksson KF, Lindgärde F. Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise The 6-year Malmö feasibility study. Diabetologia. 1991 Dec 1;34(12):891-8.
  101. Eriksson KF, Lindgärde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise. Diabetologia. 1998 Aug 1;41(9):1010-6.
  102. Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?. Diabetes care. 2004 Nov 1;27(11):2676-81.
  103. Goldberg IJ. Diabetic dyslipidemia: causes and consequences. The Journal of Clinical Endocrinology & Metabolism. 2001 Mar 1;86(3):965-71.
  104. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength?. World journal of diabetes. 2014 Aug 15;5(4):444.
  105. Lukic L, Lalic NM, Rajkovic N, Jotic A, Lalic K, Milicic T, Seferovic JP, Macesic M, Gajovic JS. Hypertension in obese type 2 diabetes patients is associated with increases in insulin resistance and IL-6 cytokine levels: potential targets for an efficient preventive intervention. International journal of environmental research and public health. 2014 Mar 28;11(4):3586-98.
  106. Zhou MS, Wang A, Yu H. Link between insulin resistance and hypertension: What is the evidence from evolutionary biology?. Diabetology & metabolic syndrome. 2014 Jan 31;6(1):12.
  107. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clinical Gastroenterology and Hepatology. 2004 Mar 31;2(3):262-5.
  108. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World journal of gastroenterology: WJG. 2008 Jan 14;14(2):185.
  109. Jansen PL. Non-alcoholic steatohepatitis. European journal of gastroenterology & hepatology. 2004 Nov 1;16(11):1079-85.
  110. Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y, Kawamura M, Ebihara K, Onji M. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition. 2007 Jan 31;23(1):46-52.
  111. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005 Mar 1;54(3):603-8.
  112. https://www.medicinenet.com/script/main/art.asp?articlekey=16295
  113. http://www.diabetesincontrol.com/glycosylation/
  114. World Health Organisation 2011. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of a WHO consultation. WHO Geneva. www.who.int/diabetes/publications/report-hba1c_2011.pdf
  115. Shimodaira M, Okaniwa S, Hanyu N, Nakayama T. Optimal hemoglobin A1c levels for screening of diabetes and prediabetes in the Japanese population. Journal of diabetes research. 2015 May 31;2015.
  116. Florkowski C. HbA1c as a diagnostic test for diabetes mellitus–reviewing the evidence. The Clinical Biochemist Reviews. 2013 Aug;34(2):75.
  117. Aldasouqi SA, Gossain VV. Update on diabetes diagnosis: A historical review of the dilemma of the diagnostic utility of glycohemoglobin A1c and a proposal for a combined glucose-A1c Diagnostic Method. Annals of Saudi medicine. 2012 May 1;32(3).
  118. Hundal RS, Inzucchi SE. Metformin. Drugs. 2003 Sep 1;63(18):1879-94.
  119. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Khunti K. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. Bmj. 2007 Feb 8;334(7588):299.
  120. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl j Med. 2002 Feb 7;2002(346):393-403.
  121. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. Journal of Clinical Investigation. 2000 Dec 1;106(11):1305.
  122. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000 Dec 1;49(12):2063-9.
  123. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Canadian Medical Association Journal. 2009 Jan 6;180(1):32-9.
  124. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl j Med. 2007 Jun 14;2007(356):2457-71.
  125. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus. American Journal of Cardiovascular Drugs. 2011 Apr 1;11(2):115-28.
  126. Hirst, J.A., Farmer, A.J., Dyar, A., Lung, T.W.C. and Stevens, R.J., 2013. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.
  127. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002 Dec 1;51(suppl 3):S368-76.
  128. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocrine-related cancer. 2009 Dec 1;16(4):1103-23.
  129. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case–control study. Acta diabetologica. 2009 Dec 1;46(4):279.
  130. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism. 2013 Jul 31;62(7):922-34.
  131. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002 Feb 28;122(2):531-44.
  132. Sun F, Yu K, Yang Z, Wu S, Zhang Y, Shi L, Ji L, Zhan S. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Experimental diabetes research. 2012 Dec 26;2012.
  133. Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. European journal of endocrinology. 2009 Jun 1;160(6):909-17.
  134. Chao EC, Henry RR. SGLT2 inhibition—a novel strategy for diabetes treatment. Nature reviews drug discovery. 2010 Jul 1;9(7):551-9.
  135. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin on the maximum capacity of the renal tubules to reabsorb glucose. Journal of Clinical Investigation. 1951 Feb;30(2):125.
  136. Liu J, Li L, Li S, Jia P, Deng K, Chen W, Sun X. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Scientific Reports. 2017;7.
  137. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni M, Matthews DR, Tsapas A. Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 DiabetesA Systematic Review and Meta-analysis. Annals of internal medicine. 2013 Aug 20;159(4):262-74.
  138. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia. 2007 Mar 1;50(3):549-54.
  139. Ahrén B. Dipeptidyl peptidase-4 inhibitors. Diabetes care. 2007 Jun 1;30(6):1344-50.
  140. Lyu X, Zhu X, Zhao B, Du L, Chen D, Wang C, Liu G, Ran X. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Scientific Reports. 2017;7.
  141. Zhang Z, Chen X, Lu P, Zhang J, Xu Y, He W, Li M, Zhang S, Jia J, Shao S, Xie J. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovascular diabetology. 2017 Mar 1;16(1):31.
  142. https://www.webmd.com/diet/obesity/gastric-bypass-operations
  143. Wu GZ, Cai B, Yu F, Fang Z, Fu XL, Zhou HS, Zhang W, Tian ZQ. Meta-analysis of bariatric surgery versus non-surgical treatment for type 2 diabetes mellitus. Oncotarget. 2016 Dec 27;7(52):87511.
  144. Smith BR, Schauer P, Nguyen NT. Surgical approaches to the treatment of obesity: bariatric surgery. Endocrinology and metabolism clinics of North America. 2008 Dec 31;37(4):943-64.
  145. Schauer PR, Mingrone G, Ikramuddin S, Wolfe B. Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care. 2016 Jun 1;39(6):902-11.
  146. http://www.webmd.com/diet/obesity/gastric-bypass
  147. https://www.diabetes.org.uk/about_us/news/surgery-must-be-recognised-as-treatment-option-for-type-2-diabetes
  148. Thaler JP, Cummings DE. Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009 Jun;150(6):2518-25.
  149. https://sciencebasedmedicine.org/the-importance-and-limitations-of-peer-review/
  150. Dancik BP. Importance of Peer Review. The Serials Librarian. 1991 Feb 12;19(3-4):91-4.
  151. Misra S. Randomized double blind placebo control studies, the “Gold Standard” in intervention based studies. Indian journal of sexually transmitted diseases. 2012 Jul;33(2):131.
  152. https://www.nbt.nhs.uk/sites/default/files/filedepot/incoming/Randomisation_in_clinical_trials.pdf
  153. Neuman J, Korenstein D, Ross JS, Keyhani S. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. BMJ. 2011 Oct 11;343:d5621.
  154. Norris SL, Holmer HK, Ogden LA, Burda BU, Fu R. Conflicts of interest among authors of clinical practice guidelines for glycemic control in type 2 diabetes mellitus. PloS one. 2013 Oct 14;8(10):e75284.
  155. Bhatt AA, Choudhari PK, Mahajan RR, Sayyad MG, Pratyush DD, Hasan I, Javherani RS, Bothale MM, Purandare VB, Unnikrishnan AG. Effect of a low-calorie diet on restoration of normoglycemia in obese subjects with type 2 diabetes. Indian Journal of Endocrinology and Metabolism. 2017 Sep;21(5):776.
  156. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011 Oct 1;54(10):2506-14.
  157. Fugh-Berman A. How basic scientists help the pharmaceutical industry market drugs. PLoS biology. 2013 Nov 19;11(11):e1001716.
  158. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2015;12.
  159. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet. 2017 Dec 5.
  160. Ades PA, Savage PD, Marney AM, Harvey J, Evans KA. Remission of recently diagnosed type 2 diabetes mellitus with weight loss and exercise. Journal of cardiopulmonary rehabilitation and prevention. 2015 May;35(3):193.
  161. Mottalib A, Sakr M, Shehabeldin M, Hamdy O. Diabetes remission after nonsurgical intensive lifestyle intervention in obese patients with type 2 diabetes. Journal of diabetes research. 2015 May 31;2015.
  162. Pierce M. Type 2 diabetes: prevention and cure? 2013.
  163. Steven S, Hollingsworth KG, Al-Mrabeh A, Avery L, Aribisala B, Caslake M, Taylor R. Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders. Diabetes care. 2016 May 1;39(5):808-15.
  164. Brehm BJ, Seeley RJ, Daniels SR, D’alessio DA. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. The Journal of Clinical Endocrinology & Metabolism. 2003 Apr 1;88(4):1617-23.
  165. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. The Lancet. 2014 Jun 13;383(9933):1999-2007.
  166. Katz DL. Diet and diabetes: lines and dots. The Journal of nutrition. 2014 Apr 1;144(4):567S-70S.
  167. Asif M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. Journal of education and health promotion. 2014;3.
  168. Rendell M. Advances in diabetes for the millennium: nutritional therapy of type 2 diabetes. Medscape General Medicine. 2004;6(3 Suppl).
  169. Parikh, P., McDaniel, M. C., Ashen, M. D., Miller, J. I., Sorrentino, M., Chan, V., … & Sperling, L. S. (2005). Diets and cardiovascular disease: an evidence-based assessment. Journal of the American College of Cardiology, 45(9), 1379-1387.
  170. Aragon, A. A., Schoenfeld, B. J., Wildman, R., Kleiner, S., VanDusseldorp, T., Taylor, L., … & Stout, J. R. (2017). International society of sports nutrition position stand: diets and body composition. Journal of the International Society of Sports Nutrition, 14(1), 16.
  171. Jeor, S. T. S., Howard, B. V., Prewitt, T. E., Bovee, V., Bazzarre, T., Eckel, R. H., & AHA Nutrition Committee. (2001). Dietary protein and weight reduction. Circulation, 104(15), 1869-1874.
  172. Johnstone, A. M., Horgan, G. W., Murison, S. D., Bremner, D. M., & Lobley, G. E. (2008). Effects of a high-protein ketogenic diet on hunger, appetite, and weight loss in obese men feeding ad libitum. The American journal of clinical nutrition, 87(1), 44-55.
  173. Jallinoja, P., Niva, M., Helakorpi, S., & Kahma, N. (2014). Food choices, perceptions of healthiness, and eating motives of self-identified followers of a low-carbohydrate diet. Food & nutrition research, 58(1), 23552.
  174. Hu, T., Mills, K. T., Yao, L., Demanelis, K., Eloustaz, M., Yancy Jr, W. S., … & Bazzano, L. A. (2012). Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: a meta-analysis of randomized controlled clinical trials. American journal of epidemiology, 176(suppl_7), S44-S54.
  175. Brehm, B. J., Seeley, R. J., Daniels, S. R., & D’alessio, D. A. (2003). A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. The Journal of Clinical Endocrinology & Metabolism, 88(4), 1617-1623.
  176. Adam‐Perrot, A., Clifton, P., & Brouns, F. (2006). Low‐carbohydrate diets: nutritional and physiological aspects. Obesity reviews, 7(1), 49-58.
  177. Prakash, D., Gupta, C., & Sharma, G. (2012). Importance of phytochemicals in nutraceuticals. J Chin Med Res Develop, 1, 70-8.
  178. Kendall, C. W., Esfahani, A., & Jenkins, D. J. (2010). The link between dietary fibre and human health. Food Hydrocolloids, 24(1), 42-48.
  179. Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007). Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiological reviews, 87(2), 507-520.
  180. Hu FB, Van Dam RM, Liu S. Diet and risk of type II diabetes: the role of types of fat and carbohydrate. Diabetologia. 2001 Jul 1;44(7):805-17.
  181. Slavin JL. Whole grains, refined grains and fortified refined grains: What’s the difference?. Asia Pacific journal of clinical nutrition. 2000 Oct 1;9(S1).
  182. Schwab U, Lauritzen L, Tholstrup T, Haldorsson TI, Riserus U, Uusitupa M, Becker W. Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review. Food & nutrition research. 2014 Jan 1;58(1):25145.
  183. Snorgaard O, Poulsen GM, Andersen HK, Astrup A. Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes. BMJ Open Diabetes Research and Care. 2017 Feb 1;5(1):e000354.
  184. Tay, J., Luscombe-Marsh, N. D., Thompson, C. H., Noakes, M., Buckley, J. D., Wittert, G. A., … & Brinkworth, G. D. (2015). Comparison of low-and high-carbohydrate diets for type 2 diabetes management: a randomized trial. The American journal of clinical nutrition, 102(4), 780-790.
  185. Jung HS. Clinical implications of glucose variability: chronic complications of diabetes. Endocrinology and Metabolism. 2015 Jun 1;30(2):167-74.
  186. Suh S, Kim JH. Glycemic variability: how do we measure it and why is it important?. Diabetes & metabolism journal. 2015 Aug 1;39(4):273-82.
  187. Westman EC, Yancy WS, Mavropoulos JC, Marquart M, McDuffie JR. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutrition & metabolism. 2008 Dec 19;5(1):36.
  188. Georgoulis M, Kontogianni MD, Yiannakouris N. Mediterranean diet and diabetes: prevention and treatment. Nutrients. 2014 Apr 4;6(4):1406-23.
  189. Pérez-Guisado, J., Muñoz-Serrano, A., & Alonso-Moraga, Á. (2008). Spanish Ketogenic Mediterranean Diet: a healthy cardiovascular diet for weight loss. Nutrition journal, 7(1), 30.
  190. Tapsell, L. C. (2014). Foods and food components in the Mediterranean diet: supporting overall effects. BMC medicine, 12(1), 100.
  191. Esposito, K., Maiorino, M. I., Bellastella, G., Chiodini, P., Panagiotakos, D., & Giugliano, D. (2015). A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. BMJ open, 5(8), e008222.
  192. Esposito, K., Maiorino, M. I., Petrizzo, M., Bellastella, G., & Giugliano, D. (2014). The effects of a Mediterranean diet on the need for diabetes drugs and remission of newly diagnosed type 2 diabetes: follow-up of a randomized trial. Diabetes care, 37(7), 1824-1830.
  193. https://www.nhs.uk/chq/pages/1862.aspx?categoryid=51
  194. Gonçalves Reis CE, Dullius J. Glycemic acute changes in type 2 diabetics caused by low and high glycemic index diets. Nutricion hospitalaria. 2011;26(3).
  195. Willett W, Manson J, Liu S. Glycemic index, glycemic load, and risk of type 2 diabetes. The American journal of clinical nutrition. 2002 Jul 1;76(1):274S-80S.
  196. Juanola-Falgarona M, Salas-Salvadó J, Ibarrola-Jurado N, Rabassa-Soler A, Díaz-López A, Guasch-Ferré M, Hernández-Alonso P, Balanza R, Bulló M. Effect of the glycemic index of the diet on weight loss, modulation of satiety, inflammation, and other metabolic risk factors: a randomized controlled trial. The American journal of clinical nutrition. 2014 Jul 1;100(1):27-35.
  197. Bhupathiraju SN, Tobias DK, Malik VS, Pan A, Hruby A, Manson JE, Willett WC, Hu FB. Glycemic index, glycemic load, and risk of type 2 diabetes: results from 3 large US cohorts and an updated meta-analysis. The American journal of clinical nutrition. 2014 Jul 1:ajcn-079533.
  198. Fabricatore AN, Wadden TA, Ebbeling CB, Thomas JG, Stallings VA, Schwartz S, Ludwig DS. Targeting dietary fat or glycemic load in the treatment of obesity and type 2 diabetes: a randomized controlled trial. Diabetes research and clinical practice. 2011 Apr 30;92(1):37-45.  
  199. Jenkins DJ, Kendall CW, McKeown-Eyssen G, Josse RG, Silverberg J, Booth GL, Vidgen E, Josse AR, Nguyen TH, Corrigan S, Banach MS. Effect of a low–glycemic index or a high–cereal fiber diet on type 2 diabetes: A randomized trial. Jama. 2008 Dec 17;300(23):2742-53.
  200. Kelly KR, Haus JM, Solomon TP, Patrick-Melin AJ, Cook M, Rocco M, Barkoukis H, Kirwan JP. A low-glycemic index diet and exercise intervention reduces TNFα in isolated mononuclear cells of older, obese adults. The Journal of nutrition. 2011 Jun 1;141(6):1089-94.
  201. Wolever TM, Gibbs AL, Mehling C, Chiasson JL, Connelly PW, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA. The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. The American journal of clinical nutrition. 2008 Jan 1;87(1):114-25.
  202. Tarantino G, Citro V, Finelli C. Hype or Reality: Should Patients with Metabolic Syndrome-related NAFLD be on the Hunter-Gatherer (Paleo) Diet to Decrease Morbidity?. J Gastrointestin Liver Dis. 2015 Sep 1;24(3):359-68.
  203. https://www.scientificamerican.com/article/why-paleo-diet-half-baked-how-hunter-gatherer-really-eat/
  204. Lindeberg S, Jönsson T, Granfeldt Y, Borgstrand E, Soffman J, Sjöström K, Ahrén B. A Palaeolithic diet improves glucose tolerance more than a Mediterranean-like diet in individuals with ischaemic heart disease. Diabetologia. 2007 Sep 1;50(9):1795-807.
  205. http://thepaleodiet.com/the-intrinsic-variation-in-hunter-gatherer-diets-why-there-is-no-one-ideal-paleo-diet/
  206. Ströhle A, Hahn A, Sebastian A. Latitude, local ecology, and hunter-gatherer dietary acid load: implications from evolutionary ecology. The American journal of clinical nutrition. 2010 Oct 1;92(4):940-5.
  207. Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA, O’Keefe JH, Brand-Miller J. Origins and evolution of the Western diet: health implications for the 21st century. The American journal of clinical nutrition. 2005 Feb 1;81(2):341-54.
  208. Konner M, Eaton SB. Paleolithic nutrition: twenty-five years later. Nutrition in Clinical Practice. 2010 Dec;25(6):594-602.
  209. Tay, J., Thompson, C. H., & Brinkworth, G. D. (2015). Glycemic variability: assessing glycemia differently and the implications for dietary management of diabetes. Annual review of nutrition, 35, 389-424.
  210. Slavin JL, Jacobs D, Marquart L. Grain processing and nutrition. Critical Reviews in Food Science and Nutrition.. 2000 Jul 1;40(4):309-26.
  211. Carluccio, M. A., Siculella, L., Ancora, M. A., Massaro, M., Scoditti, E., Storelli, C., … & De Caterina, R. (2003). Olive oil and red wine antioxidant polyphenols inhibit endothelial activation. Arteriosclerosis, thrombosis, and vascular biology, 23(4), 622-629.
  212. Tsitouras, P. D., Gucciardo, F., Salbe, A. D., Heward, C., & Harman, S. M. (2008). High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrine axes in healthy older adults. Hormone and metabolic research, 40(03), 199-205.
  213. Asif M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. Journal of education and health promotion. 2014;3..
  214. French SA, Story M, Jeffery RW. Environmental influences on eating and physical activity. Annual review of public health. 2001 May;22(1):309-35.
  215. Popkin BM. Urbanization, lifestyle changes and the nutrition transition. World development. 1999 Nov 30;27(11):1905-16.
  216. Wilmot EG, Edwardson CL, Achana FA, Davies MJ, Gorely T, Gray LJ, Khunti K, Yates T, Biddle SJ. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia. 2012 Nov 55(11):2895-2905.
  217. Healy GN, Matthews CE, Dunstan DW, Winkler EA, Owen N. Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003–06. European heart journal. 2011 Jan 11;32(5):590-7.
  218. Ng SW, Howard AG, Wang HJ, Su C, Zhang B. The physical activity transition among adults in China: 1991–2011. obesity reviews. 2014 Jan 1;15(S1):27-36.
  219. Bell AC, Ge K, Popkin BM. The road to obesity or the path to prevention: motorized transportation and obesity in China. Obesity. 2002 Apr 1;10(4):277-83.
  220. Morris JN, Crawford MD. Coronary heart disease and physical activity of work. British Medical Journal. 1958 Dec 20;2(5111):1485.
  221. Balkau B, Mhamdi L, Oppert JM, Nolan J, Golay A, Porcellati F, Laakso M, Ferrannini E. Physical activity and insulin sensitivity. Diabetes. 2008 Oct 1;57(10):2613-8.
  222. George ES, Rosenkranz RR, Kolt GS. Chronic disease and sitting time in middle-aged Australian males: findings from the 45 and Up Study. International Journal of Behavioral Nutrition and Physical Activity. 2013 Feb 8;10(1):20.
  223. Matthews CE, George SM, Moore SC, Bowles HR, Blair A, Park Y, Troiano RP, Hollenbeck A, Schatzkin A. Amount of time spent in sedentary behaviors and cause-specific mortality in US adults. The American journal of clinical nutrition. 2012 Feb 1;95(2):437-45.
  224. Peddie MC, Bone JL, Rehrer NJ, Skeaff CM, Gray AR, Perry TL. Breaking prolonged sitting reduces postprandial glycemia in healthy, normal-weight adults: a randomized crossover trial. The American journal of clinical nutrition. 2013 Aug 1;98(2):358-66.
  225. Van Dijk JW, Manders RJ, Tummers K, Bonomi AG, Stehouwer CD, Hartgens F, Van Loon LJ. Both resistance-and endurance-type exercise reduce the prevalence of hyperglycaemia in individuals with impaired glucose tolerance and in insulin-treated and non-insulin-treated type 2 diabetic patients. Diabetologia. 2012 May 1;55(5):1273-82.
  226. Henriksen EJ. Invited review: Effects of acute exercise and exercise training on insulin resistance. Journal of Applied Physiology. 2002 Aug 1;93(2):788-96.
  227. Huang S, Czech MP. The GLUT4 glucose transporter. Cell metabolism. 2007 Apr 4;5(4):237-52.
  228. Bacchi E, Negri C, Zanolin ME, Milanese C, Faccioli N, Trombetta M, Zoppini G, Cevese A, Bonadonna RC, Schena F, Bonora E. Metabolic effects of aerobic training and resistance training in type 2 diabetic subjects. Diabetes care. 2012 Apr 1;35(4):676-82.
  229. Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, Mikus CR, Myers V, Nauta M, Rodarte RQ, Sparks L. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. Jama. 2010 Nov 24;304(20):2253-62.
  230. Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, Horton ES, Castorino K, Tate DF. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016 Nov 1;39(11):2065-79.
  231. Balducci S, Zanuso S, Cardelli P, Salvi L, Bazuro A, Pugliese L, Maccora C, Iacobini C, Conti FG, Nicolucci A, Pugliese G. Effect of high-versus low-intensity supervised aerobic and resistance training on modifiable cardiovascular risk factors in type 2 diabetes; the Italian Diabetes and Exercise Study (IDES). PloS one. 2012 Nov 21;7(11):e49297.
  232. Little JP, Gillen JB, Percival ME, Safdar A, Tarnopolsky MA, Punthakee Z, Jung ME, Gibala MJ. Low-volume high-intensity interval training reduces hyperglycemia and increases muscle mitochondrial capacity in patients with type 2 diabetes. Journal of applied physiology. 2011 Dec 1;111(6):1554-60.
  233. Madsen SM, Thorup AC, Overgaard K, Jeppesen PB. High intensity interval training improves glycaemic control and pancreatic β cell function of type 2 diabetes patients. PloS one. 2015 Aug 10;10(8):e0133286.
  234. https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/diabetes-and-healthy-eating
  235. https://www.diabetes.org.uk/Guide-to-diabetes/Enjoy-food/Eating-with-diabetes/What-is-a-healthy-balanced-diet/
  236. https://www.diabetes.org.uk/Guide-to-diabetes/Enjoy-food/Eating-with-diabetes/Food-groups/fruit-and-diabetes/
  237. http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002279
  238. https://www.brown.edu/research/projects/oster/sites/brown.edu.research.projects.oster/files/uploads/Diabetes_and_Behavior_Change_FullPaper.pdf
  239. https://www.ncbi.nlm.nih.gov/pubmed/16512956
  240. https://healthyforgood.heart.org/Eat-smart/Articles/Monounsaturated-Fats
  241. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427084/
  242. http://www.eatingwell.com/article/16372/8-ways-to-follow-the-mediterranean-diet-for-better-health/
  243. https://www.nhs.uk/news/diabetes/more-people-need-know-type-2-diabetes-reversible-argues-report/
  244. https://www.bmj.com/content/358/bmj.j4030.full 
  245. https://onlinelibrary.wiley.com/doi/abs/10.1002/pdi.1835